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Reply to the Editor:
I appreciate the comments of Santise and
colleagues regarding the role of extracorpo-
real membrane oxygenation (ECMO) in the
care of patients with refractory cardiogenic
shock. Clearly, ECMO has been, and will
probably always remain, a useful treatment
in the ever-changing armamentarium op-
tions for this critically ill group. It is still
the primary option for pediatric patients,
but the frequency of its use for adults has
been significantly reduced thanks to im-
proved short-term ventricular support de-
vices (eg, CentriMag, Abiomed). Such
devices provide more reliable support, with
markedly improved durability with respect
to the Bio-Medicus systems, the first gener-
ation of short-term ventricular assist devices.
ECMO certainly offers the advantage of
avoiding a median sternotomy, as well as
the opportunity for rapid institution of sup-
port in the catheterization laboratory and
the intensive care unit, as Santise and col-
leagues report. The use of ECMO is limited,
however, by its main drawbacks: limited
durability and significant neurologic and
peripheral vascular complications. The
incidence of such complications may be af-
fected by technologic advances in the design
of ECMO circuits and oxygenators or by
altered peripheral cannulation techniques.
Several published studies, some involving
pediatric patients, have looked at the use
of ECMO for a wide range of indications
(eg, graft failure after lung transplantation,
right ventricular failure after heart transplan-
tation, postcardiotomy assistance, resuscita-
tion after cardiac arrest, and bridge to bridge
support for cardiogenic shock). All these
series reported a mean ECMO duration of
about 4 days or less.1-5 In one large, experi-
enced single-center series, the complica-
tions during ECMO were as follows:
infectious, 49%; renal failure requiring dial-
ysis, 40%; neurologic, 33%; and limb com-
plications, 25%.2 Of course, not all such
complications are related to ECMO itself.
Instead, they often are a result of the critical
condition of a patient with multiorgan dys-
function. Further, all such complications
(with the relative exception of limb compli-
cations) can also potentially occur with
short-term ventricular assist devices.
In conclusion, I agree with Santise and
colleagues that there is definitely a place
for ECMO in the treatment of patients with
acute cardiogenic shock. In the near future,
we do not know what the interplay will be
between surgical and percutaneous devices,
including ECMO. Until then, it remains im-
perative that we continue to be innovative,
open-minded, and aggressive, continually
striving to improve outcomes for this criti-
cally ill group of patients.
Ranjit John, MD
Division of Cardiothoracic Surgery
University of Minnesota
Minneapolis, MN 55455
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Letters to the EditorCirculatory support system as
a bridge to decision in patients
with refractory acute
cardiogenic shock: Is there
a space for extracorporeal
membrane oxygenation?
To the Editor:
We read with interest the timely report by
John and colleagues1 about the elective
use of the Levitronix CentriMag as a bridge
to decision in cardiogenic shock. We com-
mend them for their encouraging results in
12 patients assisted with biventricular
support.
Although the concept of cardiac assis-
tance as bridge to decision is well addressed
by the authors, we believe that extracorpo-
real membrane oxygenation (ECMO) could
play a more valuable role in this context.
This is especially so when the expected as-
sistance time is relatively short (eg, an aver-
age support length of 9.4 days, as reported in
John and colleagues’ experience1).
In our institution, we routinely use both
ECMO and the Levitronix device. The latter
is mainly used for patients with postcardiot-
omy syndrome or primary graft failure; we
advise the use of ECMO in nonsurgical
situations, such as cardiogenic shock after
acute myocardial infarction or failed percu-
taneous coronary interventions.
In this selected group of patients, ECMO
offers some advantages. These include
avoidance of sternotomy and central cannu-
lation, which may cause catastrophic bleed-
ing after aggressive thrombolysis and
antiplatelet treatment, and ease of emer-
gency implantation, even in the intensive
care unit or catheter laboratory, with conse-
quent rapid institution of assistance.
Furthermore, newly designed oxygena-
tors and ECMO circuits (Quadrox Jostra,
Permanent Life Support PLS; MAQUET
GmbH & Co KG, Rastatt, Germany) require
a lower priming volume and present a bio-
inert surface treatment, guaranteeing assis-
tance for an extended 14 days with
a reduced risk of device-related compli-
cations and a less strict anticoagulation
regimen. Moreover, ECMO can be easily
switched to cardiopulmonary bypass at the
time of transplantation or long-term device
implantation.
In our institution, since the beginning
of 2006, the PLS ECMO system has
been extensively used to treat either lung
(6 patients) or cardiac (8 patients) failure
(venovenous and venoarterial cannulation,respectively). No device failures have been
recorded, even for assistance extending
longer than 60 days.
In our experience, ECMO units are man-
aged by intensive care unit nurses, and ded-
icated personnel are usually not required.
Activated thromboplastin time is kept
between 40 and 50 seconds, with a level of
antithrombin III activity greater than 80%.
In cases of bleeding, we have withheld
heparin for more than 30 hours without
any thrombotic events.
Leg ischemia, related to common femo-
ral artery cannulation, is the complication
we have seen most frequently. In most cases,
however, this condition can be resolved by
cannulating the superficial femoral artery
as well with a small perfusion cannula.
In conclusion, although the many advan-
tages offered by the Levitronix pump are
remarkable, patient-tailored assistance can
be achieved for selected candidates with
new versions of ECMO systems, such as
the PLS. Thanks to modern technology,
these systems couple ease of implantation
and management with device reliability
and long-term durability.
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